Drug Search Results
Using advanced filters...
Advanced Search [+]

Tiplimotide

Alternative Names: tiplimotide, nbi-5788, nbi5788, nbi 5788
Latest Update: 2008-03-21
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: Unknown

Novel Mechanism: No

Modality: Large Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Neurocrine
Company Location: SAN DIEGO CA 92130
Company CEO: Kevin C. Gorman
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Multiple Sclerosis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

NBI-5788-0201

P2

Completed

Multiple Sclerosis

None

Recent News Events

Date

Type

Title